Chinese clinical oncology最新文献

{"title":"Bibliometrics of gastric cancer prediction models.","authors":"Fei Gao, Xiaohan Wang, Xifeng Fu, Jingchao Sun","doi":"10.21037/cco-24-63","DOIUrl":"https://doi.org/10.21037/cco-24-63","url":null,"abstract":"<p><p>This paper analyzes the manuscripts in the field of gastric cancer (GC) prediction, guiding clinical work and prevention of GC. Using a search strategy, we retrieved research articles related to GC prognosis from the Web of Science (WOS) core database: topic search (TS) = ((gastric cancer OR stomach cancer) AND (survival rate OR survival analysis OR prognosis) AND (predict model)). We set the language to English, the document type to article and review, and completed the search on July 1, 2023. We obtained 1,598 relevant articles, and two researchers screened the search results again, excluding irrelevant, misclassified, and retracted articles. Any controversial articles were reviewed by a third researcher to make the final decision on the required literature. We finally selected 1,056 articles, excluding 542 articles, and extracted the required data from the WOS database for analysis. The extracted database included: title, publication year, author, country/region, institution, citation count, journal, keyword, and reference. We used R (4.3.0) to load the R package (bibliometrix) for bibliometric analysis. The 1,056 articles came from 273 sources (journals, books, etc.), and 3,661 authors conducted relevant research on GC prognosis models. Frontiers in Oncology published the most articles (N=72), and Gastric Cancer Journal had the most citations (N=1,130). The publication time span ranged from 1991 to 2023, with an average annual growth rate of 13.31%. The number of publications increased from 2017, with a sharp increase from 2020 to 2023. The five countries with the most publications were China (n=826), Japan (n=62), Korea (n=47), USA (n=42), Italy (n=19). China had the most citations (N=9,595), and USA had the highest average citation per article (44.9 times). The most common topic was GC survival (n=236), followed by expression (n=209). Multiple GC prediction models in this study describe the science of predicting GC incidence and prognosis. This work provides the most influential references related to GC prediction and serves as a guide for citable papers.</p>","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":"14 1","pages":"6"},"PeriodicalIF":2.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143623900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative prognosis of liver transplantation versus liver resection in intrahepatic cholangiocarcinoma: a systematic review and meta-analysis.","authors":"Ying Chen, Hongyu Shen, Ruiqin Xu, Jiahai Zhu, Ya Zhu, Hao Zou","doi":"10.21037/cco-24-86","DOIUrl":"https://doi.org/10.21037/cco-24-86","url":null,"abstract":"<p><strong>Background: </strong>Liver resection (LR) remains the only curative approach for patients diagnosed with intrahepatic cholangiocarcinoma (ICC). Although margin-negative resection can be achieved, long-term oncological outcomes still need improvement. Recent studies from both single and multi-institutional settings have indicated that liver transplantation (LT) could be a feasible treatment option for ICC under particular conditions. While some research has compared LT with LR in treating ICC patients, the results of these comparisons remain controversial. This meta-analysis compares the surgical outcomes of LT and LR for ICC.</p><p><strong>Methods: </strong>We conducted a thorough search of the Cochrane Library, Web of Science, and PubMed for articles comparing the ICC of LT and LR published from January 2000 to April 2024. The studies' relevance and quality were assessed independently by two investigators. Odds ratios (ORs) were utilized to evaluate dichotomous data, and fixed-effects were employed for meta-analyses.</p><p><strong>Results: </strong>Five studies were analyzed in this meta-analysis, revealing no significant difference in 1-year overall survival rates between LT and LR. However, LT showed significantly higher 3-year, and 5-year overall survival rates compared to LR, with ORs of 1.39 [95% confidence interval (CI): 1.04-1.84, P=0.02] at 3 years, 1.71 (95% CI: 1.30-2.26, P<0.001) at 5 years. The advantage of LT over LR in terms of overall survival became evident at 3 years, 5 years, and post-operation, despite not being apparent in the first year. Additionally, the R0 resection rate was higher following LT than LR (P=0.006), potentially contributing to the superior long-term outcomes of LT. Subgroup analysis revealed no statistically significant difference in survival outcomes between the two treatment regimens when LT failed to achieve R0 resection.</p><p><strong>Conclusions: </strong>For patients with ICC, LT seems to have optimistic survival results under certain conditions compared with curative hepatectomy. Since LT is a potential treatment for ICC, it is currently uncertain whether LT should be more considered in patients with ICC. Further prospective trials are required to demonstrate its efficacy in the future.</p>","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":"14 1","pages":"3"},"PeriodicalIF":2.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143623889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intriguing future: single-site robotic-assisted radical prostatectomy.","authors":"Di Gu, Yubo Wang, Yifan Chang, Yongda Liu, Mingzhao Li, Chao Cai, Shancheng Ren, Guohua Zeng","doi":"10.21037/cco-24-96","DOIUrl":"10.21037/cco-24-96","url":null,"abstract":"<p><p>Single-site robotic-assisted radical prostatectomy (ssRARP) has emerged as a promising advancement in urological surgery, driven by the development of advanced robotic instrumentation and single-port access technologies. Global researchers have extensively explored various techniques and approaches for ssRARP in carefully selected patient populations, yielding promising perioperative and oncological outcomes. This review aims to provide a comprehensive overview of the technical intricacies of ssRARP. We will delve into the evolution of single-port robotic surgery, highlighting key advancements and surgical techniques, including transperitoneal, extraperitoneal, and transvesical approaches. A detailed discussion of technical nuances, challenges, and potential pitfalls will be presented. Furthermore, we will analyze the available evidence regarding the perioperative and oncological outcomes of ssRARP. This includes examining factors such as operative time, blood loss, postoperative complications, length of hospital stay, continence recovery, and biochemical recurrence-free survival, and the challenges and management strategies for patients with specific preoperative situations, such as previous surgery, large median lobe and prostatectomy after focal therapy. The potential advantages of ssRARP, including improved cosmesis, reduced postoperative pain, and faster recovery, will be explored. By providing a comprehensive understanding of the technical aspects, clinical outcomes, and future directions of ssRARP, this review aims to contribute to the ongoing discourse on the role of single-port robotic surgery in prostate cancer management.</p>","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":" ","pages":"9"},"PeriodicalIF":2.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143482299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunotherapy resistance in colorectal cancer with liver metastases: challenges & therapeutic advances.","authors":"Nosakhare Paul Ilerhunmwuwa, Ibrahim Halil Sahin, Anwaar Saeed","doi":"10.21037/cco-24-93","DOIUrl":"10.21037/cco-24-93","url":null,"abstract":"<p><p>Colorectal cancer (CRC) remains one of the leading causes of cancer-related mortality worldwide, with liver metastasis (LM) being the most common site of spread. The emergence of immunotherapy has changed the landscape of cancer treatment, providing therapeutic options for the management of CRC, especially in metastatic settings. Typically, CRC with microsatellite instability-high (MSI-H) status respond more favorably than those that are microsatellite stable (MSS). However, it has been observed that the presence of LMs limits the efficacy of immunotherapy irrespective of the microsatellite instability (MSI) status, which presents unique challenges in managing CRC with LMs (CRCLM). The exact mechanisms for resistance to immunotherapy in CRCLM are poorly understood. Several factors in the liver tumor microenvironment (TME) have been linked to therapeutic failures with immunotherapy in CRCLM. Novel agents that explore and target immunosuppressive elements in the liver TME, such as the lymphocyte activation gene 3 (LAG-3) and vascular endothelial growth factor receptor (VEGFR), in combination with anti-programmed death-1/ligand-1 (PD-1/PD-L1) have been found to improve immunotherapy response in CRCLM. Machine learning-based bioinformatics may provide further understanding of the several molecular mechanisms in the liver TME that may represent potential areas for therapeutic options and precision cancer medicine. This manuscript explores the challenges associated with immunotherapy in this subset of patients, focusing on TME, immune resistance mechanisms, and potential strategies to enhance immunotherapeutic outcomes.</p>","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":" ","pages":"7"},"PeriodicalIF":2.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143482312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel treatment vs. standard of care in melanoma-associated leptomeningeal metastases: a systematic review and network meta-analysis.","authors":"Jia Jia Teo, Angad Chauhan, Razan Nossier, Tuan Zea Tan, Vincent Diong Weng Nga","doi":"10.21037/cco-24-104","DOIUrl":"https://doi.org/10.21037/cco-24-104","url":null,"abstract":"<p><strong>Background: </strong>Melanoma stands out as a prevalent instigator of leptomeningeal disease (LMD) within the realm of cancer. Given the poor prognosis accompanying this condition, ongoing trials are exploring a spectrum of treatment modalities in pursuit of more effective interventions. To ascertain the most effective therapeutic strategies, we aim to compare novel treatments against the current standard of care for melanoma-associated LMD.</p><p><strong>Methods: </strong>A comprehensive search was conducted across multiple databases, including PubMed/Medline, EMBASE, Scopus, ScienceDirect and Web of Science for relevant studies published from January 2014 to September 2024. We included primary research studies, including observational studies, randomised control trials, quasi-experimental design studies, clinical trials, and experimental studies focusing on LMD caused by metastatic melanoma. Data extraction was conducted according to PRISMA guidelines and quality assessment/risk of bias was performed individually using the GRADE method. A network meta-analysis is conducted to evaluate the effects of multiple interventions within the study. Overall survival outcomes were quantified using log hazard ratio. The protocol for this study was registered on PROSPERO (CRD42024529626).</p><p><strong>Results: </strong>Out of 843 records screened for eligibility, seven carefully chosen studies, meeting our specific inclusion criteria, provided insights into the management of 397 patients grappling with LMD due to metastatic melanoma. These studies vary in design: one observational cohort study with 29 participants, a clinical trial with 25 patients, four retrospective cohort studies ranging from 39 to 190 participants and one experimental study with 24 patients. The chosen studies contain moderate to high risks of bias, with low heterogeneity (I2=13.4%). Immunotherapy with or without targeted therapy is the most effective intervention.</p><p><strong>Conclusions: </strong>Despite the escalating breakthroughs of treatment options in melanoma-associated LMD, further studies may be imperative to conclusively determine whether the newer therapeutic options yield superior outcomes compared to the current standard of care.</p>","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":"14 1","pages":"4"},"PeriodicalIF":2.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143622992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Befotertinib in first-line treatment for Chinese non-small cell lung cancer patients harboring common EGFR-mutations reveals similar efficacy to other third-generation EGFR-TKIs but somewhat different safety profile.","authors":"Jens Benn Sørensen, Eric Santoni-Rugiu, Edyta Maria Urbanska","doi":"10.21037/cco-24-19","DOIUrl":"10.21037/cco-24-19","url":null,"abstract":"","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":" ","pages":"88"},"PeriodicalIF":2.1,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142281028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Postoperative concurrent chemoradiotherapy plus apatinib for patients with high-grade glioma: a retrospective cohort study.","authors":"Lvjuan Cai, Jing Feng, Xiaoyan Li, Wenmin Ying, Guo Li, Huachun Luo, Xinpeng Wang, Mengjing Wu, Zhichao Fu","doi":"10.21037/cco-24-51","DOIUrl":"https://doi.org/10.21037/cco-24-51","url":null,"abstract":"<p><strong>Background: </strong>Radiotherapy plus temozolomide followed by adjuvant temozolomide was the standard treatment for high-grade gliomas. This study aimed to explore the effectiveness and safety of the addition of apatinib in patients with high-grade gliomas after surgery.</p><p><strong>Methods: </strong>In this retrospective cohort study, patients with high-grade glioma [World Health Organization (WHO) grade III or IV] treated with apatinib and concurrent chemoradiotherapy (cCRT) after surgery from October 2017 to February 2021 were reviewed. High-grade glioma patients used cCRT alone in the same period were reviewed as the control group. Progression-free survival (PFS), overall survival (OS), the grade of peritumoral brain edema (PTBE) and safety profiles were recorded. Cox regression analyses were used to determine the associated factors of PFS and OS.</p><p><strong>Results: </strong>A total of 60 patients with high-grade glioma were reviewed, with 30 patients in the apatinib plus cCRT group and 30 patients in the cCRT group. The median PFS of the apatinib plus cCRT group compared with the cCRT group was 8.53 vs. 7.33 months (P=0.62), and the median OS was 13.70 vs. 14.30 months (P=0.93). Multivariate analysis revealed that only pathological grade was independently associated with PFS [hazard ratio (HR) =4.445, 95% confidence interval (CI): 1.857 to 10.641, P<0.001] and OS (HR =3.737, 95% CI: 1.530 to 9.123, P=0.004). The apatinib plus cCRT also improved PTBE (P=0.001), and decrease the corticosteroids use than cCRT alone (P=0.002). No grade 3 or higher adverse event was observed in both groups.</p><p><strong>Conclusions: </strong>Post-operative cCRT plus apatinib was feasible for patients with high-grade glioma, with manageable toxicities.</p>","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":"13 6","pages":"82"},"PeriodicalIF":2.1,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142977961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial intelligence assistance during upper endoscopy: a game changer in detection of esophageal squamous cell carcinoma?","authors":"Annemijn D I Maan, Arjun D Koch","doi":"10.21037/cco-24-46","DOIUrl":"10.21037/cco-24-46","url":null,"abstract":"","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":" ","pages":"89"},"PeriodicalIF":2.1,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141916195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The differences in the distribution characteristics and prognostic value of tumor-infiltrating T lymphocyte subsets between lung adenocarcinoma and lung squamous cell carcinoma.","authors":"Zhen Zhang, Shaoyan Zhang, Yalai Xu, Xiaoning Liu, Wenjie Dong","doi":"10.21037/cco-24-62","DOIUrl":"https://doi.org/10.21037/cco-24-62","url":null,"abstract":"<p><strong>Background: </strong>The characteristics of tumor immune microenvironment are important factors affecting the efficacy of immunotherapy, and there are differences in the distribution of tumor-infiltrating lymphocyte (TIL) subsets in different types of tumors. This study aims to compare the distributions of cluster of differentiation (CD) 4+ and CD4+ T cell subsets of TILs and their clinical significance between lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC).</p><p><strong>Methods: </strong>The tumor tissues of 78 LUAD and 56 LUSC patients who underwent surgery at The Second Affiliated Hospital of Zhengzhou University between October 2020 and October 2022 were collected, TIL level were detected by pathological observation, and the proportions of CD4+, CD4+ T cell subsets and CD4+/CD4+ ratio in TILs were detected by flow cytometry. These indicators were compared between LUAD and LUSC, and their correlations with clinicopathological characteristics and patient survival were analyzed.</p><p><strong>Results: </strong>There was no significant difference in the TILs level between LUAD and LUSC (P>0.05). The CD4+/CD4+ ratio in LUSC was lower, and proportion of CD4+ T cells was higher than those in LUAD (all P<0.05). In LUAD, the proportions of CD4+, CD4+ T cells and CD4+/CD4+ were correlated with tumor size or tumor-node-metastasis (TNM) stage, while in LUSC, only the proportions of CD4+ and CD4+ T cells were correlated with tumor size, degree of differentiation or TNM stage. In LUAD patients, higher proportions of CD4+, CD4+ T cells and lower CD4+/CD4+ predicted longer survival, and high CD4+/CD4+ (>1.04) was an independent risk factor for PFS and OS (P<0.05); In LUSC patients, there was no correlation between the proportions of CD4+ T cells, CD4+ T cells and CD4+/CD4+ ratio, and patient prognosis (P>0.05).</p><p><strong>Conclusions: </strong>There were differences in the distribution and balance of CD4+ and CD4+ TIL subsets between LUAD and LUSC, among which CD4/CD4+ ratio closely affected the prognosis of LUAD patients but had relatively weak prognostic value in LUSC patients due to the restriction of CD4+ T cells.</p>","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":"13 6","pages":"83"},"PeriodicalIF":2.1,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142977969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dural metastases in breast cancer: progression pattern, treatment and prognosis-a single center experience.","authors":"Yujie Wang, Yimin Han, Yanzhao Yang, Cheng Xu","doi":"10.21037/cco-24-30","DOIUrl":"10.21037/cco-24-30","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Dural metastasis (DM) remains one of the most challenging clinical scenarios in breast cancer treatment. To date, no clear standard care of dural metastases has been established. We sought to identify the progression pattern or treatment strategies that could possibly improve prognosis of breast cancer patients with DM.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;Patients with breast cancer diagnosed with radiological confirmed dural metastases excluding leptomeningeal invasion alone or meningeal invasion subsequent to brain parenchyma metastases between 2014 and 2021 in single center were reviewed. All patients underwent head-enhanced magnetic resonance imaging (MRI). Imaging information, treatment and prognostic data were recorded.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;A total of 66 breast cancer patients were analyzed in this study, with 50 survival status including 43 deaths. Hormone receptors positive [estrogen receptor (ER)/progesterone receptor (PR)] accounted for 43.9% of the study cohorts followed by triple-negative breast cancer (TNBC) and HER2+ subtypes successively. Most cases (34, 51.5%) were diagnosed without parenchymal brain metastases prior to or at time of DM diagnosis. Three morphological patterns were determined by MRI including nodular, thickened with nodules, and diffuse thickened types. The frontoparietal dura was the most frequently involved site, accounting for 43.9% (29/66) of the patients, followed by temporal dura and parietal dura, ranking second and third (21/66 and 15/66, respectively). Fifty-four patients had extensive bone metastasis before the diagnosis of DM, within them, the median duration from bone metastasis to the diagnosis of DM was 419 days. Forty-two patients received radiotherapy for DM, including 25 with whole brain radiotherapy (WBRT), 4 with craniospinal axis irradiation (CSI), and 13 with DM and/or brain parenchyma lesions. Multivariate analysis indicates that initial diagnosis age, brain metastasis status, neurological symptoms and systemic treatment status and are significant prognostic factors (P=0.002, 0.03, 0.02, 0.001 and 0.02, respectively). The median survival time from the diagnosis of DM was 458 days in patients who received radiotherapy compared with 225 days in patients who did not receive radiotherapy, with a hazard ratio (HR) 0.65 [95% confidence interval (CI): 0.302-1.305] and P value of 0.06. Leptomeningeal invasion, parenchymal brain metastases and number of DM-involved sites were associated with the medical decision of WBRT. There were more leptomeningeal invasion cases distributed to WBRT group (17/29 vs. 7/37, P=0.001), and a higher likelihood of concurrent parenchymal brain lesions (19/27 vs. 13/37, P=0.01).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;Dural metastases can occur as a subsequent event in patients with poorly controlled extensive bone metastases, with the frontoparietal area being the most commonly involved site. Radiotherapeutic strategy is highly influenced","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":" ","pages":"81"},"PeriodicalIF":2.1,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142806161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}